There are 177 papers on HMGCR in aging research: 20 trials and 38 observational studies in people, 49 in animals, 20 in cells, 41 reviews.
11 new papers in 30 daysSee all 177 papers on HMGCR
At a glance
The findings reach people, from one lab or study. 17 independent labs in 8 countries; 238 trials, 153 with no results posted.
“The lipid-lowering variants of HMGCR, PCKS9, LPL, and APOB were associated with longer lifespans but did not causally increase extreme longevity.”
2 of its findings point the other way.
- 17 independent labs in 8 countries
- 2 findings against
- 238 trials, 153 with no results posted
- Funders: National Natural Science Foundation of China and others
- 2 of 23 findings with company ties
- 148 of 238 trials sponsored by developers of drugs aimed at it
- Human trial20
- Humans38
- Animals44
- Model organisms5
- Cells20
- In silico1
Interventions
4Caloric restriction
upin rats1downin rats1
2 studies
Caloric restriction
upin rats1downin rats1
Caloric restriction increases HMGCR in aging rats.
Animalsin aging rats
Caloric restriction decreases HMGCR in rats during ageing.
Animalsduring ageingliver
Flavonoids and their metabolites
downin reviews1
1 study
Flavonoids and their metabolites
downin reviews1
Flavonoids and their metabolites inhibit HMGCR (management of hyperlipidaemia).
Reviewmanagement of hyperlipidaemia
Resveratrol
downin mice1
1 study
Resveratrol
downin mice1
Resveratrol decreases HMGCR in SAMP8 mice.
Animalsin SAMP8 micecerebellum
Vitamin E
upin rats1
1 study
Vitamin E
upin rats1
Vitamin E increases HMGCR in rats.
Animalsliver
Effects
6Appendicular lean mass
no changein humans1upin humans1
2 studies
Appendicular lean mass
no changein humans1upin humans1
HMGCR was not clearly linked with appendicular lean mass in humans (genetically proxied inhibition, two-sample Mendelian randomization) (beta 0.048 (95% CI -0.015 to 0.110), P = 0.14).
Humansgenetically proxied inhibition, two-sample Mendelian randomization
HMGCR is linked with higher appendicular lean mass in humans (genetically proxied inhibition, Mendelian randomization using UK Biobank LDL-C data) (beta = 0.087, P = 7.56 × 10-5).
Humansgenetically proxied inhibition, Mendelian randomization using UK Biobank LDL-C data
Osteoarthritis
downin mice1
1 study
Osteoarthritis
downin mice1
HMGCR decreases osteoarthritis in OA mice via intra-articular AAV delivery.
Animalsin OA mice via intra-articular AAV deliverysynovium
Cognitive function
downin silico1
1 study
Cognitive function
downin silico1
HMGCR impairs cognitive function in Parkinson's disease.
In silicoin Parkinson's disease
Lifespan
upin flies1
1 study
Lifespan
upin flies1
HMGCR extends lifespan in flies (cardiac Hmgcr upregulation).
Model organismscardiac Hmgcr upregulationheart
Cardiac function
upin flies1
1 study
Cardiac function
upin flies1
HMGCR improves cardiac function in flies (cardiac Hmgcr upregulation).
Model organismscardiac Hmgcr upregulationheart
Walking pace
downin humans1OR 0.918
1 study
Walking pace
downin humans1OR 0.918
HMGCR is linked with worse walking pace in humans (genetically proxied inhibition, Mendelian randomization using UK Biobank LDL-C data) (OR = 0.918, P = 6.06 × 10-9).
Humansgenetically proxied inhibition, Mendelian randomization using UK Biobank LDL-C data
Upstream
1TFCP2
upin human cells1
1 study
TFCP2
upin human cells1
TFCP2 activates HMGCR in combination with SREBP2.
Cellsin combination with SREBP2
Associations
13Prostate cancer
downin humans1downin silico1OR 0.718–0.833
2 studies
Prostate cancer
downin humans1downin silico1OR 0.718–0.833
HMGCR is linked with a lower risk of prostate cancer in humans (genetically proxied inhibition, drug-target Mendelian randomization) (OR 0.718 (95% CI 0.559-0.924)).
Humansgenetically proxied inhibition, drug-target Mendelian randomization
HMGCR lowers the risk of prostate cancer in silico (Mendelian randomization IVW (GWAS ID: ieu-b-85)) (OR 0.833, 95% CI 0.726-0.954).
In silicoMendelian randomization IVW (GWAS ID: ieu-b-85)
Abdominal aortic aneurysm
upin humans1
1 study
Abdominal aortic aneurysm
upin humans1
HMGCR raises the risk of abdominal aortic aneurysm in humans.
Review
Cellular senescence
upin humans1
1 study
Cellular senescence
upin humans1
HMGCR is associated with cellular senescence in knee synovium of OA patients and OA mice.
Humansin knee synovium of OA patients and OA mice
Fasting blood glucose
upin humans1
1 study
Fasting blood glucose
upin humans1
HMGCR is associated with fasting blood glucose in humans.
Humans
Type 2 diabetes
upin humans1OR 3.59
1 study
Type 2 diabetes
upin humans1OR 3.59
HMGCR is linked with a higher risk of type 2 diabetes in humans (male non-smokers and light smokers) (OR 3.59, 95% CI 1.37–9.39, p = 0.0094).
Humansmale non-smokers and light smokersmales
Clear cell ovarian cancer
mixedin humans1
1 study
Clear cell ovarian cancer
mixedin humans1
HMGCR is associated with clear cell ovarian cancer in humans (gene expression instrument, Mendelian randomization).
Humansgene expression instrument, Mendelian randomizationfemales
Major depressive disorder
upin humans1OR 1.16
1 study
Major depressive disorder
upin humans1OR 1.16
HMGCR is linked with a higher risk of Major depressive disorder in humans (genetically proxied inhibition) (OR 1.16, 95% CI 1.07-1.25).
Humansgenetically proxied inhibition
Lanosterol
mixedin humans1
1 study
Lanosterol
mixedin humans1
HMGCR is associated with lanosterol in humans.
Humansserum
Dementia
downin humans1OR 0.24
1 study
Dementia
downin humans1OR 0.24
HMGCR is linked with a lower risk of dementia in humans (genetic proxy for non-HDL-C lowering, shown by one-sample Mendelian randomization) (OR 0.24 (0.18-0.31)).
Humansgenetic proxy for non-HDL-C lowering, shown by one-sample Mendelian randomizationper 1 mmol/L (39 mg/dL) lower non-HDL-C
Osteoporosis
downin humans1
1 study
Osteoporosis
downin humans1
HMGCR is linked with a lower risk of osteoporosis in humans (genetically proxied lipid-lowering variants (Mendelian randomization); also PCSK9).
Humansgenetically proxied lipid-lowering variants (Mendelian randomization); also PCSK9